{
  "docId": "019dd923-622b-71dc-a6da-b5a73e942b75",
  "docSlug": "2f97af42be51",
  "documentTitle": "Depomed, Inc. (DEPO)",
  "authorId": "03_Starboard_Value",
  "authorName": "Jeffrey C. Smith",
  "documentKindSlug": "shareholder-letter",
  "documentKindLabel": "Shareholder letter",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2016-04-08 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 2,
  "pageCount": 5,
  "prevPage": 1,
  "nextPage": 3,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "This is a text-heavy slide from a shareholder letter, likely part of a proxy contest.",
  "elementsJson": [
    "paragraph",
    "numbered_list"
  ],
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6da-b5a73e942b75/2",
  "deckHref": "/decks/019dd923-622b-71dc-a6da-b5a73e942b75",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6da-b5a73e942b75.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-b5a73e942b75#slide-2",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "These are not typical or standard provisions that would reasonably be included in such a reincorporation proposal.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-f5d1-75b6-b067-7cc39c389ff3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.75,
        "x": 0.15,
        "y": 0.15
      },
      "kind": "list",
      "text": "(i) Increase the solicitation requirement to call a special meeting from 10% of the voting power, as it currently stands under California law, to 25% of the voting power, as would be required under Depomed-Delaware’s bylaws; and (ii) Eliminate altogether the ability of shareholders to call a special meeting to remove and replace current Board members; and (iii) Prevent shareholders, for all practical purposes, from commencing a special meeting request process within 180 days of any Annual Meeting; and (iv) Obtain the sole discretion and authority to effect the Delaware reincorporation at any time prior to the 2017 Annual Meeting.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f14ef2c-a17d-444c-92fb-2ebfa02c20c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.1,
        "y": 0.4
      },
      "kind": "paragraph",
      "text": "These are not typical or standard provisions that would reasonably be included in such a reincorporation proposal. These appear to be carefully crafted provisions with the specific intention of further limiting shareholder rights. In addition, Depomed conveniently failed to disclose some of these material provisions in the Reincorporation Proposal section of its preliminary proxy and instead chose to bury these significant entrenchment provisions in Appendices D and E towards the very end of the proxy. We intend to vigorously oppose the current version of the Reincorporation Proposal, and we advise other shareholders to fully consider these provisions and the significant ramifications they would have on shareholder rights.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a27a0d8-8730-4ba9-813b-f4196f8a0145",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.1,
        "y": 0.58
      },
      "kind": "paragraph",
      "text": "Unfortunately, these shareholder-unfriendly tactics are just the latest attempts by the current Board to further entrench themselves. The Board took similar actions following Horizon’s unsolicited proposal to acquire the Company. Specifically, on July 7, 2015, the Company received an unsolicited offer from Horizon to acquire all of the outstanding shares of Depomed in an all-stock transaction for $29.25 per share, which represented a 42% premium to the closing price of $20.64 per share on July 6, 2015. At the time, this $29.25 per share offer price would have represented an all-time high stock price for the Company, and compares to the current Depomed stock price of $15.00 per share as of yesterday’s close.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17637cca-9edd-40f9-8639-91965ce9df66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.8,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Rather than engage with Horizon in an attempt to negotiate a value-maximizing transaction, on July 12, 2015, the Board adopted bylaw amendments, as well as a 10% poison pill rights plan (the “Poison Pill”), designed to make it as difficult and time-consuming as possible for shareholders to potentially have a say on Horizon’s offer at a special meeting. Nevertheless, Horizon proceeded to comply with the arduous steps under the special meeting bylaw amendments in order to give shareholders a voice on its offer. Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”), two leading proxy advisory firms, expressed concerns about Depomed’s shareholder-unfriendly bylaw amendments and Poison Pill, and supported Horizon’s efforts to call a special meeting to remove and replace the Board, noting:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "802b185c-bd05-4c03-ab30-58fc9edb60d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.1,
        "y": 0.09
      },
      "kind": "paragraph",
      "text": "bylaw provisions in July 2015, as part of its efforts to fend off an unsolicited proposal to acquire the Company from Horizon Pharma plc (“Horizon”). Now, under the guise of the Reincorporation Proposal, the Board is attempting to:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9fb8ce31-7770-4724-b7a2-eebe04a8c4f2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 3,
      "from": 2,
      "beatId": "5ec8123d-eabe-4ac5-b9b4-df915edd4d4b",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "The document presents a clear problem and complication on pages 2-3.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}